Please join hosts Craig Roush, Senior Counsel, and Jon Witt, Partner, as they discuss current U.S. M&A Lower- Mid-Market (US$25 million – $250 million) trends in Q3 of 2023.
Much has been said about the return of M&A in 2023, and while there are deals happening, it is not the boom that many expected. Additionally, in this changing climate, aspects of middle-market M&A that were once uncommon have begun to standardize and vice versa. In this webinar, speakers will break down the current status of the United States M&A Market in Q3.
To learn more and register to attend, please click here.
People
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.